Canada Insulin Drugs And Delivery Devices Market Size (2024 - 2029)

The market size for insulin drugs and delivery devices in Canada is projected to experience growth over the forecast period from 2024 to 2029. This growth is influenced by factors such as the cost of insulin in Canada, which attracts individuals from the United States seeking more affordable options. Despite legal restrictions on importing unapproved drugs, regulatory bodies generally allow personal imports of limited quantities, particularly for those looking to save on medication costs while traveling.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Diabetes Care Research Insulin Drugs And Delivery Devices Market in Canada Market Size

Market Size of Canada Insulin Drugs And Delivery Devices Industry

Canada Insulin Drugs And Delivery Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 1.68 Billion
Market Size (2029) USD 1.83 Billion
CAGR (2024 - 2029) 1.70 %

Major Players

Canada Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Canada Insulin Drugs And Delivery Devices Market Analysis

The Canada Insulin Drugs And Delivery Devices Market size is estimated at USD 1.68 billion in 2024, and is expected to reach USD 1.83 billion by 2029, growing at a CAGR of 1.7% during the forecast period (2024-2029).

In Canada, however, a vial of insulin costs less than USD 50. People looking for cheaper insulin are increasingly flying north from all over the United States to stock up. Although it is technically illegal to import unapproved drugs from Canada, regulators usually do not object to patients looking to save money while on vacation. According to the FDA's website, people importing less than a three-month supply of a drug for personal use "typically do not object."

Canada Insulin Drugs And Delivery Devices Industry Segmentation

Insulin pens are equipped with preloaded insulin to administer insulin injections. Various types of insulin pens, such as "smart" or connected ones, are available in the market. Your healthcare provider will provide detailed instructions on how to effectively utilize these pens. Canada's Insulin Drugs and Delivery Devices Market is segmented into Drugs and devices. The report offers the value (in USD) and volume (in Units) for the above segments.

Drug
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

Canada Insulin Drugs And Delivery Devices Market Size Summary

The Canada Insulin Drugs and Delivery Devices Market is poised for steady growth, driven by the increasing prevalence of diabetes and advancements in insulin delivery technologies. The market is characterized by a shift towards more innovative and efficient insulin delivery systems, such as insulin pumps, which offer continuous insulin administration and improved blood glucose management. These technological advancements are gaining preference over traditional methods due to their ability to provide near-physiological insulin delivery and reduce the pain and variability associated with injections. Despite the high costs associated with insulin pump therapy, including the initial investment and ongoing monthly supplies, there is a strong push from organizations like Diabetes Canada to remove financial and administrative barriers, ensuring broader access to these advanced therapies for individuals with type 1 diabetes.

The market landscape in Canada is consolidated, with a few major players dominating the scene. Companies like Eli Lilly, Boehringer Ingelheim, and Novo Nordisk are actively engaged in collaborations and strategic alliances to enhance their market presence and develop innovative insulin therapies. Recent regulatory approvals, such as those for the Medtronic Guardian 4 CGM sensor and the MiniMed 780G system, highlight the ongoing commitment to integrating advanced technology in diabetes management. These developments are expected to further drive market growth, as they offer more convenient and effective solutions for insulin delivery, catering to the evolving needs of diabetes patients in Canada.

Explore More

Canada Insulin Drugs And Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Basal or Long-acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Device

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

Canada Insulin Drugs And Delivery Devices Market Size FAQs

The Canada Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.68 billion in 2024 and grow at a CAGR of 1.7% to reach USD 1.83 billion by 2029.

In 2024, the Canada Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.68 billion.

Canada Insulin Drugs And Delivery Devices Market Report Snapshots

Canada Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)